Holen Sie sich die Stockscreener-App
1.10
7.56%
-0.09
Handel nachbörslich:
1.10
Schlusskurs vom Vortag:
$1.19
Offen:
$1.2
24-Stunden-Volumen:
260.79K
Relative Volume:
0.56
Marktkapitalisierung:
$60.54M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-131.52M
KGV:
-0.618
EPS:
-1.78
Netto-Cashflow:
$-107.56M
1W Leistung:
-9.47%
1M Leistung:
-13.73%
6M Leistung:
-82.73%
1J Leistung:
-66.46%
1-Tages-Spanne:
$1.095
$1.20
1-Wochen-Bereich:
$1.06
$1.22
52-Wochen-Spanne:
$0.7966
$6.80
Prelude Therapeutics Inc Stock (PRLD) Company Profile
Firmenname
Prelude Therapeutics Inc
Sektor
Branche
Telefon
(302) 467-1280
Adresse
175 INNOVATION BOULEVARD, WILMINGTON
Vergleichen Sie PRLD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PRLD
Prelude Therapeutics Inc
|
1.10 | 60.54M | 0 | -131.52M | -107.56M | -1.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
461.68 | 118.90B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
672.98 | 73.95B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
655.13 | 39.81B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.31 | 34.99B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
123.77 | 29.67B | 3.30B | -501.07M | 1.03B | -2.1146 |
Prelude Therapeutics Inc Stock (PRLD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-09-19 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2024-06-20 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2024-03-13 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2024-02-20 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2023-12-19 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2022-11-21 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-09-09 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-07-29 | Eingeleitet | Jefferies | Buy |
| 2022-03-15 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-02-28 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2021-10-08 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2021-07-27 | Hochstufung | BofA Securities | Neutral → Buy |
| 2021-04-26 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-03-09 | Eingeleitet | Barclays | Overweight |
| 2020-11-20 | Herabstufung | BofA Securities | Buy → Neutral |
| 2020-10-20 | Eingeleitet | BofA Securities | Buy |
| 2020-10-20 | Eingeleitet | Goldman | Neutral |
| 2020-10-20 | Eingeleitet | Morgan Stanley | Equal-Weight |
Alle ansehen
Prelude Therapeutics Inc Aktie (PRLD) Neueste Nachrichten
Prelude Therapeutics Reports Q3 2024 Results and Clinical Progress - MSN
D2 Capital Advisors secures $23.5m for Residence Inn in Wilmington - Hotel Management Network
Prelude Therapeutics Incorporated (NASDAQ:PRLD) Shares Purchased by Barclays PLC - Defense World
US Penny Stocks To Watch In January 2025 - Simply Wall St
Prelude Therapeutics Shares Promising Data for CDK9 Inhibitor PRT2527 - MSN
A Look At The Behavior Of Prelude Therapeutics Inc (PRLD) Stock - Stocks Register
Geode Capital Management LLC Grows Stake in Prelude Therapeutics Incorporated (NASDAQ:PRLD) - Defense World
Prelude Therapeutics Incorporated (NASDAQ:PRLD) Stake Lifted by Barclays PLC - Defense World
State Street Corp Raises Stock Position in Prelude Therapeutics Incorporated (NASDAQ:PRLD) - Defense World
Prelude Therapeutics CEO Vaddi Krishna buys $6,043 in common stock - Investing.com India
Prelude Therapeutics CEO Vaddi Krishna buys $6,043 in common stock By Investing.com - Investing.com UK
Prelude Therapeutics CEO Vaddi Krishna acquires $12,000 in stock - Investing.com
Prelude Therapeutics Incorporated (NASDAQ:PRLD) CEO Krishna Vaddi Acquires 10,000 Shares - MarketBeat
Insider Buying: Andrew Combs Acquires 63,075 Shares of Prelude T - GuruFocus.com
Andrew Combs Purchases 60,000 Shares of Prelude Therapeutics Incorporated (NASDAQ:PRLD) Stock - MarketBeat
XTX Topco Ltd Makes New $100,000 Investment in Prelude Therapeutics Incorporated (NASDAQ:PRLD) - Defense World
Krishna Vaddi Bought 4.9% More Shares In Prelude Therapeutics - Yahoo Finance UK
Insider Buying: Prelude Therapeutics Incorporated (NASDAQ:PRLD) CEO Purchases 100,000 Shares of Stock - MarketBeat
Prelude Therapeutics Incorporated (NASDAQ:PRLD) CFO Purchases $22,750.00 in Stock - MarketBeat
Prelude Therapeutics CEO Krishna Vaddi buys $99,325 in stock By Investing.com - Investing.com South Africa
Prelude Therapeutics’ interim CFO Bryant Lim buys $22,637 in stock By Investing.com - Investing.com Nigeria
Prelude Therapeutics' interim CFO Bryant Lim buys $22,637 in stock - Investing.com India
Prelude Therapeutics CEO Krishna Vaddi buys $99,325 in stock - Investing.com
Larimar Therapeutics Reports Promising Results for Friedreich’s Ataxia Treatment - MyChesCo
What Did We Find About Insider Trading At Prelude Therapeutics Inc (NASDAQ: PRLD)? - Stocks Register
Prelude Therapeutics' SWOT analysis: biotech stock faces pivotal year ahead By Investing.com - Investing.com Canada
Palvella Therapeutics and Pieris Pharmaceuticals Finalize Merger to Focus on Rare Disease Treatments - MyChesCo
PRLD Stock Touches 52-Week Low at $0.91 Amid Market Challenges - Investing.com Canada
Aprea Therapeutics Updates ABOYA-119 Trial with Twice Daily Dosing - MyChesCo
Windtree Therapeutics Files Patent for Istaroxime Derivatives to Combat Acute Myocardial Arrhythmia - MyChesCo
Prelude Therapeutics presents first interim data from trial of PRT2527 - Yahoo Finance
Prelude Therapeutics Incorporated (NASDAQ:PRLD) Position Increased by Walleye Capital LLC - Defense World
Prelude Therapeutics Presents Preliminary Results of Phase 1 Dose-escalation Study of PRT2527 - The Bakersfield Californian
Prelude Therapeutics Presents Preliminary Results of Phase 1 Dose-escalation Study of PRT2527 as Monotherapy and in Combination with Zanubrutinib in Patients with Relapsed/Refractory Lymphoid Malignancies - Yahoo Finance
Sirus Therapeutics announces positive signals from Phase I siRNA trial - Yahoo Finance
PRLD Stock Touches 52-Week Low at $0.93 Amid Market Challenges - Investing.com Nigeria
November 2024's Top Picks: Penny Stocks On US Exchanges - Simply Wall St
After Plunging -31.47% in 4 Weeks, Here's Why the Trend Might Reverse for Prelude Therapeutics (PRLD) - Yahoo Finance
Prelude Therapeutics to Participate in Citizens JMP Securities Hematology and Oncology Summit - Yahoo Finance
Prelude Therapeutics Reports Progress in Clinical Trials and Financial Health - TipRanks
Panavance Therapeutics Unveils Promising Data on Misetionamide’s Dual Cancer Targeting Mechanism - MyChesCo
Larimar Therapeutics Shares Promising Data on Nomlabofusp at Ataxia Research Congress - MyChesCo
Down -39.13% in 4 Weeks, Here's Why You Should You Buy the Dip in Prelude Therapeutics (PRLD) - MSN
Prelude Therapeutics Incorporated (NASDAQ:PRLD) Short Interest Update - MarketBeat
CERo Therapeutics, Inc. Receives FDA Clearance of Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Its Lead Compound CER-1236 in Acute Myelogenous Leukemia - Yahoo Finance
PRLD Stock Touches 52-Week Low at $1.1 Amid Market Challenges - Investing.com Australia
Prelude Therapeutics' SWOT analysis: biotech stock faces pivotal data readouts - Investing.com
Finanzdaten der Prelude Therapeutics Inc-Aktie (PRLD)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.95%
2.39%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):